Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
10+ emerging markets, Japan & ANZ transition in final phase
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
Subscribe To Our Newsletter & Stay Updated
